Pfizer Posts 56-Cent Q3 EPS as Shares Sit at 52-Week High
PFE sits 31% above its 52-week low of $23.62.
Summary
Pfizer reported third-quarter 2026 revenue of $16.58B and adjusted EPS of 87 cents, alongside GAAP EPS of 56 cents. The company raised its 2026 guidance, now seeing full-year adjusted EPS of $2.95 to $3.05 and revenue of $62B to $64B, up from its prior revenue outlook of $60.5B to $62.5B. The print lands with the stock at $30.98, just under its 52-week high of $31.04, so expectations are already elevated. Context matters here: the prior quarter (Q2 2026) was a $248 million net loss driven by $4.3 billion in asset impairments, alongside $2.5 billion of additional cost savings and a zero-tariff agreement with the U.S. government. The pipeline has also been busy — FDA approval of the updated COVID vaccine, Phase 2 win for tilrekimig, the Metsera acquisition adding a monthly GLP-1, and TUKYSA's approval — but a Florida AG lawsuit against the company and CEO Albert Bourla over marketing is an overhang.
Updates
· Reuters — Pfizer's Q3 revenue of $16.58 bln beat the $15.87 bln consensus and adjusted EPS of $0.87 beat $0.73; 2026 adjusted EPS guidance is $2.95-$3.05.
At the time of this announcement, PFE was trading at $30.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.